कोशिश गोल्ड - मुक्त
Is On-Demand Healthcare Taking Off?
BioSpectrum Asia
|May 2022
Digital healthcare is converging technology with healthcare to deliver more efficient, personalised, and innovative healthcare services through telemedicine, cloud-based mobile apps, wearable devices, clinical management devices, artificial intelligence, algorithm software, diagnostic medical devices, and more. Making use of the emerging opportunities, startups and Small and Medium Enterprises (SMEs) in Asia Pacific are accelerating their research, development, and production of emerging and disruptive technology tools. These small-scale innovators are gradually entering mainstream opportunities through collaboration with government, academics, and large industries for technological development as well as through partnership and investment opportunities. But, how far have they been successful in making a leap to thrive in the industry and overcoming the barriers? Let's dig deeper.
When the pandemic crisis struck, as a mode of business continuity, many Asia Pacific (APAC) countries accelerated digital transformation creating new opportunities across startup and SME communities. A recent survey by Health-tech company Medtronic revealed that, in around 15 markets of the APAC region, a major percentage of healthcare technology organizations opine that COVID-19 had enabled the development and implementation of innovative ideas, although the positive impact on innovation differed markedly across markets. Even in South-East Asia, telemedicine, online pharmacy, and digital health mobile application gained regional traction solving the long-time concerns about access to a broader spectrum of healthcare services, the need for affordable consultations, quicker appointments, and a significant reduction in the traveling efforts of the patients. Thanks to startups and SMEs for their quick resolutions.
Enhancing Startup and SME success
The pandemic has removed multiple institutional and cultural barriers to the adoption of digital solutions in the healthcare technology setting. Digitization has grown far more rapidly than was previously thought possible and ushered in an acceptance of remote medical products and services, and alternative care models, fostering greater industry innovation. Despite current apprehensions about data protection and regulatory concerns, the healthcare system is uplifting digital healthcare and MedTech capabilities, IoT infrastructure, and cybersecurity strengths to increase workflow efficiency and patient outcomes. Many startups and SMEs are utilising the opportunity by combining pioneering science, data, analytics, and technology to deliver better Personalised healthcare (PHC) at a reduced cost.
यह कहानी BioSpectrum Asia के May 2022 संस्करण से ली गई है।
हजारों चुनिंदा प्रीमियम कहानियों और 10,000 से अधिक पत्रिकाओं और समाचार पत्रों तक पहुंचने के लिए मैगज़्टर गोल्ड की सदस्यता लें।
क्या आप पहले से ही ग्राहक हैं? साइन इन करें
BioSpectrum Asia से और कहानियाँ
BioSpectrum Asia
India–EU FTA Paves Way for Expanded Healthcare Trade
On January 27, 2026, after years of negotiations, India and the European Union announced a landmark Free Trade Agreement.
4 mins
BioSpectrum Asia March 2026
BioSpectrum Asia
PreferCo and Glatt to open CoE for precision fermentation bioprocess scale-up in India
In a major boost to Government of India's BioE3 push, German major Glatt and India-based startup PreferCo have announced the launch of \"PreferCo-Glatt Centre of Excellence (CoE) for Bioprocess Scale-Up\" in Hyderabad's Genome Valley.
1 min
BioSpectrum Asia March 2026
BioSpectrum Asia
Women's Health Surge in APAC
The rising burden of diseases such as ovarian cancer, breast cancer, cervical cancer, infertility, etc. is emerging as the key driver of the women's healthcare market across the globe. While North America led the women healthcare market in 2025, Asia Pacific (APAC) is expected to witness the fastest growth this year onwards. As a result, governments across the APAC region, are recognising the importance of women's health and are launching initiatives, particularly under female leaders, to improve access to healthcare services. Moreover, a number of women-led startups are now developing new solutions to address this growing burden of women-associated diseases in the APAC region. Let's take a closer look.
6 mins
BioSpectrum Asia March 2026
BioSpectrum Asia
Hanchor Bio receives US FDA Orphan Drug Designation for HCB101 in gastric cancer
Taiwan-based biotech startup HanchorBio, Inc. has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to HCB101 for the treatment of gastric cancer.
1 min
BioSpectrum Asia March 2026
BioSpectrum Asia
Daiichi Sankyo names Dr John Tsai as Global Head of R&D
Japan-based Daiichi Sankyo Company has appointed Dr John Tsai to succeed Dr Ken Takeshita, who is stepping down as Global Head of R&D, effective April 1, 2026.
1 min
BioSpectrum Asia March 2026
BioSpectrum Asia
"The global trend is moving beyond centralised hubs toward distributed networks and domestic capability"
King Faisal Specialist Hospital & Research Centre (KFSHRC) and US-based Germfree Laboratories have announced a strategic partnership to develop Saudi Arabia's first fully integrated, modular Advanced Therapy Medicinal Product (ATMP) Manufacturing Campus.
4 mins
BioSpectrum Asia March 2026
BioSpectrum Asia
SEOUL'S RISKY DRUG PRICING RESET
Drug pricing has once again moved to the centre of policy debate in South Korea, with the government recently stepping back from its proposed generic drug pricing reform.
2 mins
BioSpectrum Asia March 2026
BioSpectrum Asia
Takeda and Iambic sign $1.7 B deal to advance AI driven design of small molecules
Iambic, a US-based clinical-stage life science and technology company developing novel medicines using its artificial intelligence (AI)-driven discovery and development platform, has announced a multi-year technology and discovery collaboration agreement with Japan-based Takeda Pharma that will use Iambic's industry leading AI drug discovery models to advance a select set of high-priority small molecule programmes, initially in Takeda's Oncology and Gastrointestinal and Inflammation therapeutic areas.
1 min
BioSpectrum Asia March 2026
BioSpectrum Asia
S.Biomedics announces partnership with Catalent to develop and manufacture TED-A9
US-based Catalent and South Korea-based S.Biomedics have announced a strategic partnership to support the development and manufacturing of TED-A9, S.Biomedics' allogeneic pluripotent stem-cell-derived ventral midbrain-specific dopaminergic precursor cell therapy being developed for the treatment of Parkinson's disease.
1 min
BioSpectrum Asia March 2026
BioSpectrum Asia
China revises drug administration regulations to spur innovation
China has revised regulations concerning drug administration in a bid to promote drug innovation, strengthen management of online sales of medicines and reinforce drug safety supervision.
1 min
BioSpectrum Asia March 2026
Translate
Change font size

